Allogene Therapeutics Stock: Navigating Volatility Amid Clinical Progress
09.09.2025 - 15:36:04 | boerse-global.de
Shares of Allogene Therapeutics have demonstrated significant volatility, with a recent 3.6% gain on September 8th starkly contrasting a substantial year-to-date decline of 47.9%. The stock continues to trade notably below both its 50-day and 200-day moving averages, indicating a persistent technical downtrend despite intermittent positive movements. With a market capitalization of $255.16 million, investor sentiment remains fragile.
The company’s latest quarterly results, reported on August 13th, 2025, revealed some positive financial developments. Allogene posted a net loss of $50.9 million ($0.23 per share), which came in below the consensus expectation of $0.28 per share. The company maintains a solid cash position with $302.6 million in liquid assets as of the end of the second quarter, providing an operational runway that management expects to extend into the second... Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
